Vandetanib (Caprelsa)

==General information==
Class/mechanism: from the NCI Drug Dictionary: "An orally bioavailable 4-anilinoquinazoline. Vandetanib selectively inhibits the tyrosine kinase activity of vascular endothelial growth factor receptor 2 (VEGFR2), thereby blocking VEGF-stimulated endothelial cell proliferation and migration and reducing tumor vessel permeability. This agent also blocks the tyrosine kinase activity of epidermal growth factor receptor (EGFR), a receptor tyrosine kinase that mediates tumor cell proliferation and migration and angiogenesis." Also a tyrosine kinase inhibitor of RET (rearranged during transfection), BRK (breast tumor kinase/protein tyrosine kinase 6), TIE2, EPH, Src. Inhibits angiogenesis, endothelial cell migration, and tumor growth.Vandetanib (Caprelsa) package insert Vandetanib (Caprelsa) package insert (locally hosted backup)Caprelsa manufacturer's website
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, or the prescribing information.
==Toxicity management==
*Caprelsa Risk Evaluation and Mitigation Strategy (REMS) ProgramCaprelsa Risk Evaluation and Mitigation Strategy (REMS) Program
==Diseases for which it is established (work in progress)==
*Medullary thyroid cancer
==Diseases for which it is used==
*Non-small cell lung cancer
*Thyroid cancer
**Differentiated thyroid cancer
==Patient drug information==
*Vandetanib (Caprelsa) package insertVandetanib (Caprelsa) package insert
*Vandetanib (Caprelsa) patient drug information (Chemocare)Vandetanib (Caprelsa) patient drug information (Chemocare)
*Vandetanib (Caprelsa) patient drug information (UpToDate)Vandetanib (Caprelsa) patient drug information (UpToDate)
==History of changes in FDA indication==
* 2011-04-06: Initial approval for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease. (Based on ZETA)
==History of changes in EMA indication==
*2012-02-16: Initial marketing authorization as Caprelsa.
==History of changes in Health Canada indication==
*2012-01-12: Initial notice of compliance
==History of changes in PMDA indication==
*2015-09-28: Initial approval for the treatment of unresectable medullary thyroid cancer.
==Also known as==
*Code names: AZD-6474
*Brand names: Caprelsa, Lucivand, Zactima
==References==
Category:Drugs
Category:Oral medications
Category:EGFR inhibitors
Category:PDGFR inhibitors
Category:RET inhibitors
Category:SRC inhibitors
Category:TEK inhibitors
Category:VEGFR inhibitors
Category:Non-small cell lung cancer medications
Category:Thyroid cancer, differentiated medications
Category:Thyroid cancer, medullary medications
Category:REMS program
Category:EMA approved in 2012
Category:FDA approved in 2011
Category:Health Canada approved in 2012
Category:PMDA approved in 2015